SCHEDULE: Millennium Management Files Joint Ownership Agreement

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have entered into a joint filing agreement concerning their beneficial ownership of Capricor Therapeutics, Inc. common stock.

Summary

• This filing confirms an agreement among Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander to jointly file Schedule 13G regarding their beneficial ownership of Capricor Therapeutics, Inc. common stock.
• The agreement pertains to the filing made on or about August 18, 2026.
• Millennium Management LLC and Millennium Group Management LLC are organized in Delaware, while Israel A. Englander is a U.S. citizen.
• The reporting persons collectively hold 2,857,387 shares of Capricor Therapeutics, Inc. common stock, representing 4.9% of the class.
• This filing does not represent an acquisition or holding of shares for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily a procedural agreement for joint filing of beneficial ownership information, with no new financial or strategic information.

Positives

• Confirms a coordinated approach to reporting beneficial ownership, suggesting transparency.
• The reporting persons collectively hold a significant, though not controlling, stake (4.9%) in Capricor Therapeutics, Inc.

Negatives

• The filing indicates that the reporting persons have ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing, implying a reduction in their stake below a previous threshold.

Risks

• The filing notes that the securities disclosed are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander. This structure could lead to complex control dynamics or potential conflicts of interest, although it is not explicitly stated as a risk.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• The filing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors crossing the 5% beneficial ownership threshold. This particular filing is a procedural confirmation of a joint filing arrangement among related entities, indicating coordinated investment management rather than a new strategic development for Capricor Therapeutics.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant ownership by Millennium entities, which can influence market perception. The reduction below 5% might be noted by investors.
• Management of Capricor Therapeutics: Awareness of significant, coordinated institutional ownership is important for strategic planning and investor relations.

Next Steps

• The reporting persons will continue to file Schedule 13G as required by regulations concerning beneficial ownership.
• The joint filing agreement ensures coordinated reporting of ownership stakes.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Joint Filing Agreement, Millennium Management, Capricor Therapeutics, Investment Managers, Securities Exchange Act